Drug Trial Radar · NCT07386743
A Phase III Study of GS101 Injection to Dupixent®
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
572
Planned (sponsor's estimate)
Start
Jan 29, 2026
Primary completion
Apr 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Jiangsu Genscend Biopharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a a multicenter, randomized, double-blinded, parallel, positive-controlled, Phase III comparative study to evaluate GS101 Injection versus Dupixent® in participants with moderate-to-severe atopic dermatitis. A total of 572 subjects are planned to be included and randomized at a ratio of 1:1 to receive GS101 injection or Dupixent®
Conditions
- Atopic Dermatitis (AD)
Interventions
GS101 injectionDrug
300mg/2.0mL; an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W);subcutaneous injection
DUPIXENT®Drug
300mg/2.0mL; an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every other week (Q2W); subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients achieving EASI-75 at week 16Time frame: 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.